坦桑尼亚2026-2030年新疫苗引入优先排序:多准则决策分析
乙型肝炎出生剂量疫苗综合得分最高(1.9),其次为乙型肝炎成人疫苗(3.0);疟疾和孕产妇RSV疫苗为中等优先(4.2),MMR(4.4)、Men5(4.5)和TCV(5.2)排名最低。研究建议分阶段引入乙型肝炎疫苗,并需加强监测、可持续融资和卫生系统能力。
要点
- 乙型肝炎出生剂量疫苗综合得分最高(1.9),为最优先引入疫苗。
- 乙型肝炎成人疫苗次优先(3.0),疟疾和孕产妇RSV疫苗为中等优先(4.2)。
- 关键系统制约包括冷链能力有限、融资不确定性、疫苗成本及本地流行病学和经济数据缺口。
核心结论
- MCDA通过NVI-PST为坦桑尼亚新疫苗引入提供了透明、系统且贴合情境的优先排序框架。
- 研究结果支持分阶段引入乙型肝炎疫苗,并强调需加强监测、可持续融资和卫生系统能力以促进未来疫苗采纳。
研究设计与样本
- 坦桑尼亚免疫技术咨询组(TITAG)应用多准则决策分析(MCDA),采用WHO新疫苗引入优先排序与测序工具(NVI-PST)并适配坦桑尼亚情境。
主要发现
- 乙型肝炎出生剂量疫苗综合得分最高(1.9),其次为乙型肝炎成人疫苗(3.0)。
- 疟疾和孕产妇RSV疫苗为中等优先(综合得分4.2)。
- MMR(4.4)、Men5(4.5)和TCV(5.2)排名最低。
- 识别的关键系统制约包括冷链能力有限、融资不确定性、疫苗成本以及本地流行病学和经济数据缺口。
关键数值与推荐
- 综合得分:乙型肝炎出生剂量1.9,乙型肝炎成人3.0,疟疾4.2,孕产妇RSV 4.2,MMR 4.4,Men5 4.5,TCV 5.2。
临床怎么用
- 可参考该MCDA框架和NVI-PST工具,结合本地重要性及可行性准则对新疫苗引入进行透明化优先排序。
- 优先推动乙型肝炎疫苗分阶段引入,同时针对冷链、融资和数据缺口等制约制定强化措施。
局限性
- 本地流行病学和经济数据存在缺口,可能影响评分依据的完整性。
- 融资不确定性和冷链能力有限等系统制约可能影响优先排序结果的实际可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The growing need for availability of new vaccines, alongside constrained financial and health system resources, necessitates transparent and evidence-based prioritization. METHODS: A multi-criteria decision analysis (MCDA) approach was applied by the Tanzania Immunization Technical Advisory Group (TITAG) to prioritize new vaccine introductions for 2026-2030. The World Health Organization's New Vaccine Introduction Prioritization and Sequencing Tool (NVI-PST) was adapted to the Tanzanian context. From thirteen candidate vaccines, seven were shortlisted: hepatitis B birth dose, hepatitis B (adult), malaria, measles-mumps-rubella (MMR), meningococcal (Men5), maternal respiratory syncytial virus (RSV), and typhoid conjugate vaccine (TCV). Thirteen criteria across importance (n = 9) and feasibility (n = 4) domains were applied. Evidence was compiled and vaccines were scored through a structured, participatory process. RESULTS: Hepatitis B birth dose ranked highest (combined score 1.9), followed by hepatitis B (adult) vaccine (3.0). Malaria and maternal RSV vaccines were moderate priorities (4.2), while MMR (4.4), Men5 (4.5), and TCV (5.2) ranked lowest. Key system constraints identified included limited cold chain capacity, financing uncertainties, cost of a vaccine and gaps in local epidemiological and economic data. CONCLUSION: The application of MCDA through the NVI-PST provided a transparent, systematic, and context-specific framework for prioritizing new vaccine introductions in Tanzania. The findings support phased introduction of hepatitis B vaccines while highlighting the need for strengthened surveillance, sustainable financing, and health system capacity to enable future vaccine adoption. This approach offers a practical model for other resource-constrained settings seeking to optimize immunization decision-making.
引用
- Kyesi F, Michael F, Kilonzo S, et al. Prioritizing the introduction of new vaccine in Tanzania (2026-2030): a multi-criteria decision analysis by the Tanzania immunization technical advisory group. Vaccine. 2026. PMID: 42537288. doi:10.1016/j.vaccine.2026.128985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。